We have five products that will launch in the next 12-18 months. We recently launched Yesintek in the immunology space -- a ...

This growth is driven by increasing market share, particularly in the US, where our biosimilars pegfilgrastim (Fulphila) and trastuzumab (Ogivri) now hold over 30 per cent and 26 per cent share ...

Fulphila was co-developed through a collaboration between Mylan and India’s Biocon that has produced 11 biologic and insulin products, including the FDA-approved Ogivri, a biosimilar version of ...

The company’s biosimilar business (Biocon Biologics) which constitutes 58% rose 14% YoY on a like-to-like basis to Rs 2289 crore led by market share gains for biosimilars such as Ogivri (anti ...

OGIVRI (Trastuzumab-dkst), as well as FULPHILA (Pegfilgrastim-jmdb) and the first U.S. approval of an interchangeable biosimilar for SEMGLEE (insulin glargine). Biocon Biologics has a comprehensive ...

OGIVRI (Trastuzumab-dkst), as well as FULPHILA (Pegfilgrastim-jmdb) and the first U.S. approval of an interchangeable biosimilar for SEMGLEE (insulin glargine). Biocon Biologics has a comprehensive ...

Biologics (also called biological medications) are a complex class of drugs derived from living organisms, such as plant or animal cells. They’re made by reproducing copies of living cells that ...